Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Dosing of antiretroviral medication to prevent HIV infection differs by sex

Dosing of antiretroviral medication to prevent HIV infection differs by sex

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

New guidelines integrate biomedical advances and behavioral interventions for HIV people

New guidelines integrate biomedical advances and behavioral interventions for HIV people

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Researchers launch phase II clinical trial of rectal microbicide to prevent HIV infections

Researchers launch phase II clinical trial of rectal microbicide to prevent HIV infections

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

FDA: New drug Tivicay approved to treat HIV-1 infection

FDA: New drug Tivicay approved to treat HIV-1 infection

New WHO guidelines recommend earlier treatment for people living with HIV

New WHO guidelines recommend earlier treatment for people living with HIV